- Home
- ARMN vs PRTA Comparison
ARMN vs PRTA Comparison
Compare ARMN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- PRTA
- Stock Information
- Founded
- ARMN 1992
- PRTA 2012
- Country
- ARMN Canada
- PRTA Ireland
- Employees
- ARMN N/A
- PRTA N/A
- Industry
- ARMN
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- PRTA Health Care
- Exchange
- ARMN Nasdaq
- PRTA Nasdaq
- Market Cap
- ARMN 769.7M
- PRTA 809.8M
- IPO Year
- ARMN N/A
- PRTA N/A
- Fundamental
- Price
- ARMN $4.97
- PRTA $11.29
- Analyst Decision
- ARMN
- PRTA Buy
- Analyst Count
- ARMN 0
- PRTA 9
- Target Price
- ARMN N/A
- PRTA $54.57
- AVG Volume (30 Days)
- ARMN 853.8K
- PRTA 472.0K
- Earning Date
- ARMN 05-13-2025
- PRTA 05-07-2025
- Dividend Yield
- ARMN N/A
- PRTA N/A
- EPS Growth
- ARMN 77.15
- PRTA N/A
- EPS
- ARMN 0.14
- PRTA N/A
- Revenue
- ARMN $510,604,000.00
- PRTA $135,157,000.00
- Revenue This Year
- ARMN $49.45
- PRTA N/A
- Revenue Next Year
- ARMN $4.63
- PRTA $131.75
- P/E Ratio
- ARMN $34.83
- PRTA N/A
- Revenue Growth
- ARMN 14.06
- PRTA 47.92
- 52 Week Low
- ARMN $3.29
- PRTA $11.11
- 52 Week High
- ARMN $5.16
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- ARMN 69.07
- PRTA 33.39
- Support Level
- ARMN $4.50
- PRTA $11.42
- Resistance Level
- ARMN $4.88
- PRTA $13.52
- Average True Range (ATR)
- ARMN 0.21
- PRTA 0.74
- MACD
- ARMN 0.04
- PRTA -0.16
- Stochastic Oscillator
- ARMN 86.09
- PRTA 6.36
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).